 |
| |
| Dec-19-19 | Upgrade |
Barclays |
Equal Weight → Overweight |
$173 |
|
| Dec-17-19 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
$145 → $170 |
|
| Nov-20-19 | Initiated |
Cantor Fitzgerald |
Overweight |
$160 |
|
| Oct-16-19 | Upgrade |
Atlantic Equities |
Underweight → Neutral |
|
|
| Oct-11-19 | Upgrade |
Bernstein |
Mkt Perform → Outperform |
$155 |
|
| Jul-12-19 | Resumed |
Credit Suisse |
Outperform |
$156 |
|
| May-28-19 | Initiated |
Goldman |
Buy |
|
|
| Jan-23-19 | Reiterated |
Barclays |
Equal Weight |
$137 → $135 |
|
| Jul-12-18 | Upgrade |
Goldman |
Sell → Neutral |
|
|
| Jun-27-18 | Initiated |
Bernstein |
Mkt Perform |
$129 |
|
| Apr-23-18 | Reiterated |
Citigroup |
Neutral |
$146 → $134 |
|
| Apr-18-18 | Reiterated |
Stifel |
Hold |
$145 → $135 |
|
| Jan-24-18 | Reiterated |
Stifel |
Hold |
$142 → $145 |
|
| Jan-12-18 | Reiterated |
Wells Fargo |
Outperform |
$155 → $160 |
|
| Jan-02-18 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Oct-18-17 | Reiterated |
Stifel |
Hold |
$140 → $142 |
|
| Oct-18-17 | Reiterated |
RBC Capital Mkts |
Outperform |
$144 → $147 |
|
| Oct-18-17 | Reiterated |
Leerink Partners |
Outperform |
$150 → $165 |
|
| Oct-16-17 | Reiterated |
Jefferies |
Buy |
$157 → $160 |
|
| Oct-11-17 | Upgrade |
Jefferies |
Hold → Buy |
|
|
|
|
| Feb-22-20 09:35AM | These companies are investing billions so robots can perform surgery without a doctor in the room MarketWatch |
| Feb-21-20 04:02PM | Why this local sports tech accelerator is a slam dunk for the region American City Business Journals |
| 11:30AM | Johnson & Johnson (JNJ) Down 0.1% Since Last Earnings Report: Can It Rebound? Zacks |
| 10:03AM | Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval Zacks |
| 10:00AM | This Medical Giant Slipped Below A Buy Zone Should You Bet On It? Investor's Business Daily |
| 09:07AM | JNJ Stock Continues To Hit Fresh Highs But Is It Time To Buy Shares? Investor's Business Daily |
| Feb-20-20 04:51PM | 4 Most Popular Healthcare Stocks Among Hedge Funds: Q4 Rankings Insider Monkey |
| 02:29PM | 9 secrets of dividend investing, from a couple of stock pros who beat the market MarketWatch |
| 08:00AM | ISRG Stock: Should You Invest In The Biggest Robotic Surgery Player? Investor's Business Daily |
| Feb-19-20 06:38PM | Why a Top World Stock Fund Likes Microsoft, Alibaba, and Johnson & Johnson Barrons.com |
| 10:35AM | Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs GuruFocus.com |
| 09:42AM | Sanofi, J&J Join Forces With BARDA for Coronavirus Vaccine Zacks |
| 06:00AM | Why a Top World Stock Fund Likes Microsoft, Alibaba, and Johnson & Johnson Barrons.com |
| 05:46AM | We Wouldn't Be Too Quick To Buy Johnson & Johnson (NYSE:JNJ) Before It Goes Ex-Dividend Simply Wall St. |
| Feb-18-20 10:17AM | Health-care stocks hinge on presidential politics and theyre now looking favorable MarketWatch |
| 10:00AM | Sanofi partners with U.S. agency to develop coronavirus vaccine Reuters |
| 09:30AM | Johnson & Johnson to Expand Partnership with U.S. Department of Health & Human Services to Accelerate the Discovery of Potential COVID-19 Treatments PR Newswire |
| 04:00AM | This entrepreneur booked 300% revenue growth in 2 years American City Business Journals |
| Feb-17-20 05:57PM | Pioneer Investments Buys Microsoft, Amazon, Apple GuruFocus.com |
| Feb-14-20 04:20PM | Dow Jones Today: A Day for Safe Havens InvestorPlace |
| 10:19AM | Drug wholesaler stocks falls after WSJ report that states rejected opioid settlement offer MarketWatch |
| 09:52AM | Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails Zacks |
| 08:23AM | The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering Benzinga |
| Feb-13-20 04:23PM | Dow Jones Today: Coronavirus Controversy Reemerges InvestorPlace |
| 02:25PM | 3 Dow Jones Industrial Average Stocks to Sell InvestorPlace |
| Feb-12-20 05:16PM | Johnson & Johnson to Participate in the 9th Annual SVB Leerink Global Healthcare Conference PR Newswire |
| 03:48PM | China Keeps Experts Waiting; Conference Canceled: Virus Update Bloomberg |
| 10:30AM | Buy AbbVie for its Growth Prospects, Yield and Low Valuation GuruFocus.com |
| 09:43AM | J&J (JNJ) Signs Deal With HHS to Develop Coronavirus Vaccine Zacks |
| 09:18AM | The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga |
| Feb-11-20 04:52PM | Releasing Quarantined Americans; Cruise Concerns: Virus Update Bloomberg |
| 04:44PM | J&J partners with U.S. agency to develop coronavirus vaccine Reuters |
| 04:30PM | Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine PR Newswire |
| 09:15AM | J&J Files Application for Darzalex Label Expansion With FDA Zacks |
| 07:23AM | The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga |
| Feb-10-20 02:43PM | New York Opioid Case A Significant Risk For Pharma Stocks, Says Bearish BofA Benzinga |
| 07:53AM | Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar? Zacks |
| Feb-09-20 10:45AM | 3 Compelling Stocks to Catch on Possible Recession TipRanks |
| Feb-07-20 04:29PM | Our Favorite Dividend ETF GuruFocus.com |
| 04:22PM | Coronavirus update: Business impact widens as China fights to get infections under control Yahoo Finance |
| 02:13PM | Why a Harvard professor is asking shareholders to vote away their right to sue Yahoo Finance |
| 02:09PM | With Alibaba Stock the Waiting Is the Hardest Part InvestorPlace |
| 02:07PM | AbbVie's (ABBV) Q4 Earnings Beat, 2020 View Solid, Stock Up Zacks |
| 01:11PM | T. Rowe Price Keeps Buying Fox, General Electric GuruFocus.com |
| 12:34PM | Johnson & Johnson Hit with $750M Punitive Damages Verdict for Failing to Warn about Cancer-Causing Asbestos in Talc Products PR Newswire |
| 08:19AM | Can JNJ Stock Keep on Its Current Growth Track? InvestorPlace |
| 08:18AM | Breaking: J&J to Pay $750M in Baby Powder Case Investing.com |
| 07:31AM | Stocks - U.S. Futures Point Lower; Caution Sets in Ahead of Payrolls Investing.com |
| 04:45AM | Outsmarting a Killer: Georgia inventors, researchers finding new tech to tackle heart disease American City Business Journals |
| Feb-06-20 05:50PM | Can Biotech ETFs Continue to Soar in 2020? Zacks |
| 05:36PM | J&J Brand Most Valuable Among Pharmaceutical Companies GuruFocus.com |
| 03:55PM | Jury orders Johnson & Johnson to pay $750 million in New Jersey talc case Reuters |
| 03:36PM | J&J ordered to pay $750 mln in NJ talc case -lawyer Reuters |
| 02:26PM | 64 Best Dividend Stocks You Can Count On in 2020 Kiplinger |
| 11:00AM | Glaxo (GSK) Lags Q4 Earnings & Revenue Estimates, Stock Down Zacks |
| Feb-05-20 03:19PM | FOCUS-Drugmakers see long road ahead in coronavirus vaccine race Reuters |
| 03:00PM | WHO Says There's No Effective Coronavirus Treatment Yet Benzinga |
| 11:17AM | Regeneron Expands Agreement to Develop Coronavirus Therapy Zacks |
| 10:37AM | Can Humira/Cancer Drugs Help AbbVie (ABBV) Beat Q4 Earnings? Zacks |
| 10:27AM | Theravance Pipeline Strong, Dependence on Yupelri a Concern Zacks |
| 09:47AM | Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off Zacks |
| 06:34AM | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks |
| Feb-04-20 01:19PM | Coronavirus update: China toll skyrockets, but markets calm amid government cash infusion Yahoo Finance |
| 08:03AM | AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards? Zacks |
| 01:00AM | FDA to hold public meeting on testing for asbestos in talc Reuters |
| Feb-03-20 06:49PM | Edited Transcript of JNJ earnings conference call or presentation 22-Jan-20 1:00pm GMT Thomson Reuters StreetEvents |
| 01:06PM | Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards? Zacks |
| 11:16AM | Vaxart (VXRT) to Make Vaccines to Check Coronavirus, Stock Up Zacks |
| 06:54AM | Merck (MRK) to Report Q4 Earnings: Is a Beat in the Offing? Zacks |
| Feb-01-20 03:28PM | Barron's Picks And Pans: Intel, Johnson & Johnson, T-Mobile And More Benzinga |
| Jan-31-20 11:08AM | Johnson & Johnson Is Ordered to Pay California Over Deceptive-Marketing Claim Barrons.com |
| 10:52AM | Some Drugmakers Are Racing to Develop a Coronavirus Vaccine. Why Big Pharma Isnt Rushing In. Barrons.com |
| 10:32AM | Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative Zacks |
| 07:30AM | Bayer wins EU recommendation for prostate cancer drug Reuters |
| 07:20AM | The Wining Sector & Its Top Stocks in Virus-Infected January Zacks |
| 12:56AM | PRESS DIGEST-New York Times business news - Jan 31 Reuters |
| Jan-30-20 06:21PM | J&J (JNJ) Plans to Develop Vaccine for New Coronavirus Zacks |
| 03:40PM | Coronavirus update: US records first human-to-human transmission as WHO declares global emergency Yahoo Finance |
| 12:10PM | Hedge Fund Hotels in 2020: Visa Inc (V) vs. Market Cap Peers Insider Monkey |
| 10:51AM | Biogen (BIIB) Surpasses Q4 Earnings and Sales Estimates Zacks |
| 09:43AM | Montco biopharm firm's stock surges again on new coronavirus pact American City Business Journals |
| 09:26AM | The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance Benzinga |
| Jan-29-20 01:40PM | Coronavirus update: Vaccine expected in Phase 1 trial within months, WHO to reconvene on Thursday MarketWatch |
| 12:02PM | Johnson & Johnson working on vaccine for coronavirus Reuters Videos |
| 09:55AM | How Microsoft, PepsiCo and other solid plays helped this fund manager ride out a bumpy decade MarketWatch |
| 09:54AM | Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review Zacks |
| 09:04AM | J&J begins development of coronavirus vaccine MarketWatch |
| 09:01AM | Johnson & Johnson starts developing vaccine for coronavirus Reuters |
| 08:56AM | Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More Zacks |
| 08:48AM | Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat PR Newswire |
| 05:19AM | Johnson & Johnson Says It's Working on a Coronavirus Vaccine TheStreet.com |
| Jan-28-20 10:51AM | Johnson & Johnson Is the Quintessential Recession-Proof Company GuruFocus.com |
| Jan-27-20 07:01PM | UK healthcare cost agency rejects J&J's nasal spray for depression Reuters |
| 03:43PM | J&J CEO testifies: 'I did not read all the documents' Reuters Videos |
| 02:21PM | CDC officials say coronavirus is similar to SARS, no new U.S. cases reported MarketWatch |
| 10:47AM | Your 6-point plan to navigating a choppy stock market MarketWatch |
| 10:33AM | J&J CEO questioned over stock sale ahead of story on asbestos in Baby Powder Reuters |
| 10:26AM | J&J chief testifies he did not read all documents related to asbestos in talc Reuters |
| 09:16AM | Johnson & Johnson Is 'Confident' In Ability To Treat Coronavirus, But Vaccine Could Take Time Benzinga |
| 09:15AM | Coronavirus Ends Weekly Winning Streaks Zacks |
|
|
|
|
| Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; sterilization and disinfection products to reduce surgical infection; diabetes care products; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. It has research and collaboration alliance with Morphic Therapeutic. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Ullmann Michael H | Exec VP, General Counsel | Feb 13 | Option Exercise | 0.00 | 20,326 | 0 | 152,697 | Feb 18 05:03 PM | | Wolk Joseph J | Exec VP, CFO | Feb 13 | Option Exercise | 0.00 | 7,080 | 0 | 21,387 | Feb 18 05:03 PM | | Wengel Kathryn E | EVP, Chief GSC Officer | Feb 13 | Option Exercise | 0.00 | 15,809 | 0 | 65,532 | Feb 18 05:03 PM | | Fasolo Peter | Exec VP, Chief HR Officer | Feb 13 | Option Exercise | 0.00 | 22,231 | 0 | 110,559 | Feb 18 05:03 PM | | Decker Robert J | Controller, CAO | Feb 13 | Option Exercise | 0.00 | 1,499 | 0 | 13,946 | Feb 18 05:03 PM | | Duato Joaquin | Vice Chair, Exec Committee | Feb 13 | Option Exercise | 0.00 | 105,668 | 0 | 220,373 | Feb 18 05:03 PM | | Gorsky Alex | Chairman, CEO | Feb 13 | Option Exercise | 0.00 | 107,016 | 0 | 496,472 | Feb 18 05:03 PM | | McEvoy Ashley | EVP, WW Chair, Medical Devices | Feb 13 | Option Exercise | 0.00 | 13,747 | 0 | 56,496 | Feb 18 05:03 PM | | Mongon Thibaut | Exec VP, WW Chair, Consumer | Feb 13 | Option Exercise | 0.00 | 3,692 | 0 | 57,259 | Feb 18 05:03 PM | | Sneed Michael E | EVP, Global Corp Aff & COO | Feb 13 | Option Exercise | 0.00 | 11,836 | 0 | 61,219 | Feb 18 05:03 PM | | Stoffels Paulus | Vice Chair, Exec Committee | Feb 13 | Option Exercise | 0.00 | 39,381 | 0 | 270,900 | Feb 18 05:03 PM | | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | Feb 13 | Option Exercise | 0.00 | 16,084 | 0 | 115,813 | Feb 18 05:03 PM | | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | Feb 03 | Option Exercise | 0.00 | 48,312 | 0 | 123,450 | Feb 04 07:31 PM | | McEvoy Ashley | EVP, WW Chair, Medical Devices | Feb 03 | Option Exercise | 0.00 | 38,650 | 0 | 58,154 | Feb 04 07:31 PM | | Sneed Michael E | EVP, Global Corp Aff & COO | Jan 30 | Option Exercise | 62.62 | 58,128 | 3,639,975 | 107,511 | Feb 03 06:28 PM | | Sneed Michael E | EVP, Global Corp Aff & COO | Jan 30 | Sale | 149.39 | 58,128 | 8,683,568 | 49,383 | Feb 03 06:28 PM | | Joly Hubert | Director | Dec 13 | Buy | 141.28 | 5,000 | 706,399 | 5,000 | Dec 16 04:40 PM | | Wengel Kathryn E | EVP, Chief GSC Officer | Dec 12 | Option Exercise | 62.62 | 2,017 | 126,305 | 51,736 | Dec 16 05:40 PM | | Wengel Kathryn E | EVP, Chief GSC Officer | Dec 12 | Sale | 141.07 | 2,017 | 284,538 | 49,719 | Dec 16 05:40 PM | | HEWSON MARILLYN A | Director | Jun 11 | Buy | 139.68 | 3,000 | 419,040 | 3,000 | Jun 11 05:01 PM |
|
|
|
|
|
|
